PBAC's latest decision on Clozapine: Recommended with restriction (2018). Considered for Schizophrenia in patients who are non-responsive to or intolerant of other neuroleptic agents (initial treatment), and continuing treatment in patients already stabilised on clozapine.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Adult patients with schizophrenia who are non-responsive to or intolerant of other neuroleptic agents (initial treatment phase), or patients already stabilised on clozapine for at least 18 weeks (continuing treatment phase).
Therapy area
Mental health
Line of therapy
Later-line
Evidence base
Other
Economic model
not modelled
ICER note
not-modelled — minor submission (supply shortage alternative); no economic evaluation conducted